Get the Stockscreener App
1.16
5.45%
0.06
Estrella Immunopharma Inc stock is traded at $1.16, with a volume of 8,319.
It is up +5.45% in the last 24 hours and up +26.02% over the past month.
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer and autoimmune diseases.
See More
Previous Close:
$1.10
Open:
$1.06
24h Volume:
8,319
Relative Volume:
0.06
Market Cap:
$41.97M
Revenue:
-
Net Income/Loss:
$-8.53M
P/E Ratio:
-9.9485
EPS:
-0.1166
Net Cash Flow:
$-12.75M
1W Performance:
-2.82%
1M Performance:
+26.02%
6M Performance:
+31.82%
1Y Performance:
-7.19%
1-Day Range:
$1.06
$1.19
1-Week Range:
$1.02
$1.41
52-Week Range:
$0.63
$3.23
Estrella Immunopharma Inc Stock (ESLA) Company Profile
Name
Estrella Immunopharma Inc
Sector
Industry
Phone
(510) 318-9098
Address
5858 HORTON STREET, SUITE 370, EMERYVILLE
Compare ESLA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ESLA
Estrella Immunopharma Inc
|
1.16 | 41.97M | 0 | -8.53M | -12.75M | -0.2434 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Estrella Immunopharma Inc Stock (ESLA) Latest News
Estrella Immunopharma regains Nasdaq compliance - Investing.com
Tonix Pharmaceuticals (NASDAQ:TNXP) Stock Quotes, Forecast and News Summary - Benzinga
vTv Therapeutics (NASDAQ:VTVT) Stock Quotes, Forecast and News Summary - Benzinga
Estrella Immunopharma extends stock sale agreement with White Lion By Investing.com - Investing.com Canada
Estrella Immunopharma faces Nasdaq delisting over equity shortfall - Investing.com
Chengxi Shipyard Co., Ltd. announced that it expects to receive CNY 425 million in funding from China Structural Reform Fund Co., Ltd., China Pacific Property Insurance Co., Ltd., China Life Insurance Company Limited, PICC Property and Casualty Company - Marketscreener.com
Estrella Immunopharma Inc (ESLA) Quarterly 10-Q Report - Quartzy
Spotlight On US Penny Stocks: Estrella Immunopharma And Two Others To Consider - Simply Wall St
Estrella Immunopharma Appoints Dr. Cheng Liu as CEO - TipRanks
Decoding Houlihan Lokey Inc (HLI): A Strategic SWOT Insight - Yahoo Finance Australia
Tesla stock hits 52-week low at $0.75 amid market challenges - Investing.com UK
ARMOUR Residential REIT, Inc. Announces November 2024 Dividend Rate per Common Share - Yahoo Finance Australia
Westrock Coffee Company (WEST) Moves 10.8% Higher: Will This Strength Last? - Yahoo Finance Australia
Around the Helix: Cell and Gene Therapy Company Updates – October 9, 2024 - CGTLive™
First Patient Dosed Achieves Complete Response in Estrella Immunopharma’s Trial for CD19-Targeted T-cell Therapy EB103 in B-Cell Lymphomas - CGTLive™
HP Inc. gets hit with downgrade from Citigroup - Yahoo Finance Australia
Estrella Immunopharma Inc (ESLA) Stock: A Year of Stock Market Dynamics - The InvestChronicle
Stocks to Watch: Wynn Resorts, Estrella Immunopharma, Amazon.com - MarketWatch
Stocks to Watch : Wynn Resorts, Estrella Immunopharma, Amazon.com - Marketscreener.com
BeyondSpring (BYSI) Stock Surges 6.83% Amid High Volume Trading - GuruFocus.com
Estrella Immunopharma Shares Rise on Lymphoma Patient's Treatment Response - MarketWatch
Estrella Immunopharma Achieves Complete Response in First Patient Treated with CD19- Redirected ARTEMIS - Business Wire
Best Income Stocks to Buy for September 25th - Yahoo Finance Australia
EXTR INVESTOR UPDATE: Suffer Losses on Your Extreme Networks, Inc. Investment? Contact BFA Law by October 15 about Pending Class Action Lawsuit (Nasdaq:EXTR) - ForexTV.com
Arizona State Retirement System Has $78,000 Stock Holdings in Evolv Technologies Holdings, Inc. (NASDAQ:EVLV) - Defense World
Shareholders that lost money on Extreme Networks, Inc. (EXTR) Urged to Join Class Action – Contact The Gross Law Firm to Learn More - ForexTV.com
Elutia Inc. (NASDAQ:ELUT) Sees Large Decrease in Short Interest - Defense World
Kessler Topaz Meltzer & Check, LLP Reminds Investors of - GlobeNewswire
Extra Storage rises on Jefferies upgrade - XM
Debt-Free Multibagger Stock Hit 18 Consecutive Upper Circuits & 52-Week Highs: Will the Rally Come to a Halt? - Dalal Street Investment Journal
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Extreme Networks, Inc.EXTR - PR Newswire
Extreme Networks (EXTR) Tumbled 18% After Guiding For - GlobeNewswire
Clene (NASDAQ:CLNN) Stock Quotes, Forecast and News Summary - Benzinga
The Psychology of Extreme Networks Inc. Inc. (EXTR) Price Performance: Understanding Market Sentiment - The InvestChronicle
Despite selling recently, Dell Technologies Inc. (NYSE:DELL) insiders own 50% stake and recent decline might have cost them - Yahoo Finance Australia
Estrella Immunopharma Welcomes New Chairperson, Expands Board - TipRanks
Here is What to Know Beyond Why PayPal Holdings, Inc. (PYPL) is a Trending Stock - Yahoo Finance Australia
Uptake of Nononcology Gene Therapy Remains Slow in Hematology - CGTLive™
Estrella Immunopharma appoints new chairperson to board - Investing.com India
Estrella Immunopharma Announces Appointment of Hong Zhang as Chairperson and Board Member - 01Net
ESLAWEstrella Immunopharma, Inc. Warrant Latest Stock News & Market Updates - StockTitan
Estrella Immunopharma, Inc. (NASDAQ:ESLA) Sees Large Growth in Short Interest - MarketBeat
Wall Street today: US stocks trade higher after promising inflation data raises Fed rate cut bets; 3M Co. gains 18.99% - MSN
Estrella Immunopharma’s Trial for CD19-Targeted T-cell Therapy EB103 in B-Cell Lymphomas Doses First Patient - CGTLive™
Estrella Immunopharma, Inc. (NASDAQ:ESLA) Short Interest Up 8.5% in July - MarketBeat
ESLA’s Stock Tango: The Dance of Gains and Losses in 2023 - The InvestChronicle
Wall Street today: US stocks trade higher after promising inflation data raises Fed rate cut bets; 3M Co. gains 18.99% | Stock Market News - Mint
Keppel REIT (OTCMKTS:KREVF) Sees Large Growth in Short Interest - American Banking and Market News
Apple Inc. (NASDAQ:AAPL) Shares Acquired by Saxon Interests Inc. - American Banking and Market News
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Short Interest Up 24.9% in June - American Banking and Market News
Estrella Immunopharma, Inc. (NASDAQ:ESLA) Short Interest Up 60.0% in June - MarketBeat
Estrella Immunopharma Inc Stock (ESLA) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):